PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25932626-1 2015 BACKGROUND: The concomitant use of cytochrome P450 3A4 (CYP3A4) metabolized statins (simvastatin, lovastatin, and atorvastatin) with CYP3A4 inhibitors has been shown to increase the rate of adverse events. Lovastatin 98-108 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 35-54 25932626-1 2015 BACKGROUND: The concomitant use of cytochrome P450 3A4 (CYP3A4) metabolized statins (simvastatin, lovastatin, and atorvastatin) with CYP3A4 inhibitors has been shown to increase the rate of adverse events. Lovastatin 98-108 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 56-62 25932626-1 2015 BACKGROUND: The concomitant use of cytochrome P450 3A4 (CYP3A4) metabolized statins (simvastatin, lovastatin, and atorvastatin) with CYP3A4 inhibitors has been shown to increase the rate of adverse events. Lovastatin 98-108 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 133-139 22529023-7 2012 The CYP3A4 statins (i.e., simvastatin, atorvastatin and lovastatin) accounted for 85% of all statins in 2004, increasing to 93% in 2008. Lovastatin 56-66 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 4-10 23703578-6 2013 Drug-drug interactions are dependent on statins" pharmacokinetic profile: simvastatin, lovastatin and atorvastatin are metabolized through cytochrome P450 (CYP) 3A, while the metabolism of the other statins is independent of this CYP. Lovastatin 87-97 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 139-163 23703578-14 2013 Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated. Lovastatin 16-26 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 47-52 23703578-14 2013 Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated. Lovastatin 16-26 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 116-121 23314529-2 2013 Metabolism of certain statins involves the cytochrome P450 3A (CYP3A) enzymes, and CYP3A4*22 significantly influences the dose needed for achieving optimal lipid control for atorvastatin, simvastatin, and lovastatin. Lovastatin 205-215 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 63-68 23314529-2 2013 Metabolism of certain statins involves the cytochrome P450 3A (CYP3A) enzymes, and CYP3A4*22 significantly influences the dose needed for achieving optimal lipid control for atorvastatin, simvastatin, and lovastatin. Lovastatin 205-215 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 83-89 24974574-4 2014 Simvastatin, atorvastatin and lovastatin are metabolized by CYP3A4, fluvastatin by CYP2C9, while rosuvastatin by CYP2C9 and 2C19. Lovastatin 30-40 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 60-66 24256019-12 2013 Therefore, statins metabolized through CYP3A4 (simvastatin, lovastatin and atorvastatin) are the ones with the highest number of clinically relevant interactions. Lovastatin 60-70 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 39-45 22281720-1 2012 PURPOSE: Although CYP3A4/5 enzymes play the predominant role in the metabolism of simvastatin and lovastatin, polymorphisms in CYP2D6 were reported to be associated with the cholesterol-lowering effect and/or tolerability of simvastatin. Lovastatin 98-108 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 18-24 21820929-6 2012 RESULTS: CYP3A4 was responsible for the metabolism of lovastatin, simvastatin and atorvastatin; fluvastatin depends on CYP2C9; P-glycoprotein is responsible for decreased atorvastatin, pravastatin, simvastatin and lovastatin concentrations. Lovastatin 54-64 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 9-15 21820929-6 2012 RESULTS: CYP3A4 was responsible for the metabolism of lovastatin, simvastatin and atorvastatin; fluvastatin depends on CYP2C9; P-glycoprotein is responsible for decreased atorvastatin, pravastatin, simvastatin and lovastatin concentrations. Lovastatin 214-224 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 9-15 20012601-11 2010 CONCLUSION: Lovastatin increased the absorption of verapamil by inhibiting P-gp and inhibited the first-pass metabolism of verapamil by inhibiting CYP3A4 in the intestine and/or liver in humans. Lovastatin 12-22 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 147-153 19429419-5 2009 Sulforaphane significantly suppressed the expression of MDR1 and CYP3A mRNAs induced by atorvastatin lactone, lovastatin acid, and lovastatin lactone, comparable to the control level, and moderately inhibited that by cerivastatin acid, fluvastatin acid and simvastatin lactone. Lovastatin 131-149 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 65-70 21105332-4 2010 In this review we present results of studies assessing effect of various allele variants of CYP3A4 and CYP3A5 on efficacy and tolerability of atorvastatin, lovastatin,, and simvastatin in different populations of patients. Lovastatin 156-166 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 92-98 19149415-5 2008 Triacetyloleandomycin, a specific inhibitor of human CYP3A4, inhibited the metabolism of lovastatin in pig and human liver microsomes. Lovastatin 89-99 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 53-59 18302447-4 2008 OBJECTIVE: To evaluate the incidence and clinical consequences of the use of lovastatin or simvastatin with concomitant CYP3A4 inhibitors and inducers, and with fibrates. Lovastatin 77-87 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 120-126 18302447-14 2008 CONCLUSION: Although the pharmacokinetic interactions between lovastatin or simvastatin and CYP3A4 inhibitors and inducers are substantial, their clinical relevance seems to be limited, at least with lower statin doses. Lovastatin 62-72 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 92-98 17615423-12 2007 In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors. Lovastatin 222-232 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 56-62 16857822-10 2006 The use of lovastatin, which is metabolized by CYP3A4, is contraindicated with drugs, such as gefitinib and erlotinib, which are also metabolized by CYP3A4 due to greatly enhanced toxicity. Lovastatin 11-21 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 47-53 16714062-6 2006 Among the statins, simvastatin, lovastatin and atorvastatin are metabolized by cytochrome P450 3A4 (CYP3A4) while fluvastatin is metabolized by CYP2C9. Lovastatin 32-42 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 79-98 16714062-6 2006 Among the statins, simvastatin, lovastatin and atorvastatin are metabolized by cytochrome P450 3A4 (CYP3A4) while fluvastatin is metabolized by CYP2C9. Lovastatin 32-42 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 100-106 17452418-6 2007 In Caco-2 cells, demonstrated to contain minimal CYP3A activity, the permeability coefficient of the prodrugs lovastatin and enalapril was increased in the presence of the active flavonoids kaempferol and naringenin, consistent with inhibition of esterase activity. Lovastatin 110-120 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 49-54 17178259-4 2006 Simvastatin, lovastatin, and atorvastatin are metabolized by cytochrome P450 (CYP) 3A4 (simvastatin acid is also metabolized by CYP2C8); their plasma concentrations and risk of myotoxicity are greatly increased by strong inhibitors of CYP3A4 (eg, itraconazole and ritonavir). Lovastatin 13-23 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 61-86 17178259-4 2006 Simvastatin, lovastatin, and atorvastatin are metabolized by cytochrome P450 (CYP) 3A4 (simvastatin acid is also metabolized by CYP2C8); their plasma concentrations and risk of myotoxicity are greatly increased by strong inhibitors of CYP3A4 (eg, itraconazole and ritonavir). Lovastatin 13-23 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 235-241 17233196-4 2006 Phenytoin induces the CYP3A4 isoform of the CYP450 system and can reduce the bioavailability, and thus the efficacy of the statins metabolized by this enzyme, including atorvastatin and lovastatin. Lovastatin 186-196 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 22-28 16857822-10 2006 The use of lovastatin, which is metabolized by CYP3A4, is contraindicated with drugs, such as gefitinib and erlotinib, which are also metabolized by CYP3A4 due to greatly enhanced toxicity. Lovastatin 11-21 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 149-155 12433810-2 2002 Treatment of 2- to 3-day-old human hepatocyte cultures with 3 x 10(-5) M lovastatin, simvastatin, fluvastatin, or atorvastatin for 24 h increased the amounts of CYP2B6 and CYP3A mRNA by an average of 3.8- to 9.2-fold and 24- to 36-fold, respectively. Lovastatin 73-83 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 172-177 16581329-6 2006 In persons taking simvastatin, lovastatin, or atorvastatin, 60% of cases involved drugs known to inhibit CYP3A4 (especially erythromycin and azole antifungals), and 19% involved fibrates, principally gemfibrozil. Lovastatin 31-41 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 105-111 12505310-2 2002 With the exception of pravastatin, the remaining 15 compounds transactivated the CYP3A4 reporter gene with differing inductive abilities (I(max):EC(50)) over two orders of magnitude, ranging from 1.1 (phenytoin) to 222.9 (lovastatin) in a receptor-supplemented system and it is proposed that the lack of response to pravastatin is due to loss of the known hepatic uptake transporter in HepG2 cells. Lovastatin 222-232 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 81-87 16581325-4 2006 Drug metabolism studies show simvastatin and lovastatin to be especially sensitive to the inhibiting effects of other drugs on the cytochrome P-450 3A4 (CYP3A4) isoenzyme. Lovastatin 45-55 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 131-151 16581325-4 2006 Drug metabolism studies show simvastatin and lovastatin to be especially sensitive to the inhibiting effects of other drugs on the cytochrome P-450 3A4 (CYP3A4) isoenzyme. Lovastatin 45-55 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 153-159 16581329-5 2006 Incidence was higher (4.2 per 100,000 person-years) with lovastatin, simvastatin, or atorvastatin (which are oxidized by cytochrome P450 3A4 [CYP3A4], which is inhibited by many drugs) than pravastatin or fluvastatin (which are not oxidized by CYP3A4). Lovastatin 57-67 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 121-140 16581329-5 2006 Incidence was higher (4.2 per 100,000 person-years) with lovastatin, simvastatin, or atorvastatin (which are oxidized by cytochrome P450 3A4 [CYP3A4], which is inhibited by many drugs) than pravastatin or fluvastatin (which are not oxidized by CYP3A4). Lovastatin 57-67 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 142-148 16581329-5 2006 Incidence was higher (4.2 per 100,000 person-years) with lovastatin, simvastatin, or atorvastatin (which are oxidized by cytochrome P450 3A4 [CYP3A4], which is inhibited by many drugs) than pravastatin or fluvastatin (which are not oxidized by CYP3A4). Lovastatin 57-67 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 244-250 15679472-3 2005 Some statins (atorvastatin, lovastatin and simvastatin) also requires metabolism by the cytochrome P450 3A4 system. Lovastatin 28-38 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 88-107 14522569-4 2003 Since certain lipophilic statins (i.e. simvastatin, atorvastatin, lovastatin) are a substrate of CYP3A4, we were interested in potential drug interactions between clopidogrel and statins. Lovastatin 66-76 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 97-103 11475198-4 2001 RESULT: More than 50% of the overall CYP metabolism is mediated through the isoenzyme CYP3A4, which is the main elimination route of simvastatin, lovastatin and atorvastatin. Lovastatin 146-156 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 86-92 14727985-10 2002 Simvastatin and lovastatin are significantly metabolized by cytochrome P450 enzymes (CYP3A4) and are therefore not recommended for coadministration with protease inhibitors. Lovastatin 16-26 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 85-91 11584328-7 2001 Several drugs have been shown to significantly inhibit the CYP3A4 pathway; in combination with statins such as lovastatin, simvastatin, atorvastatin, and cerivastatin, they have been shown to elevate serum concentrations of these statins, or may increase the risk of myopathy. Lovastatin 111-121 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 59-65 11005703-12 2000 Atorvastatin, cerivastatin, lovastatin and simvastatin are predominantly metabolised by the CYP3A4 isozyme. Lovastatin 28-38 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 92-98 11197581-12 2001 CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). Lovastatin 156-166 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 114-120 9929499-1 1999 In an in vitro study, the cytochrome P-450 3A (CYP3A)-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-Co A reductase inhibitors lovastatin and pravastatin were compared. Lovastatin 157-167 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 26-45 11029845-8 2000 Lovastatin, simvastatin, and atorvastatin are substrates of CYP3A4, whereas fluvastatin is metabolized by CYP2C9. Lovastatin 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 60-66 10665838-7 1999 Simvastatin, lovastatin, cerivastatin, and atorvastatin are biotransformed in the liver primarily by cytochrome P450-3A4, and are susceptible to drug interactions when co-administered with potential inhibitors of this enzyme. Lovastatin 13-23 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 101-120 11126989-3 2000 Most statins are metabolised by the CYP3A4 izoenzyme (lovastatin, simvastatin, atorvastatin, cerivastatin). Lovastatin 54-64 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 36-42 9929499-1 1999 In an in vitro study, the cytochrome P-450 3A (CYP3A)-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-Co A reductase inhibitors lovastatin and pravastatin were compared. Lovastatin 157-167 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 47-52 10548883-11 1999 Many of the PXR activators are widely used drugs such as dexamethasone, lovastatin, and rifampicin, whose induction of CYP3A levels causes them to promote the metabolism of other drugs, often with adverse consequences. Lovastatin 72-82 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 119-124 9421099-1 1997 Itraconazole strongly interacts with some drugs metabolized by cytochrome P450 3A4, for example, felodipine and lovastatin, by inhibiting their metabolism. Lovastatin 112-122 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 63-82 32729746-3 2020 Potent inhibitors of cytochrome P450 (CYP) 3A4 significantly increase plasma concentrations of the active forms of simvastatin, lovastatin, and atorvastatin. Lovastatin 128-138 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 21-46 9129558-2 1997 Itraconazole strongly interacts with some of the substrates of CYP3A4 (e.g., terfenadine, triazolam and lovastatin); hence it is important to uncover the possible interaction of itraconazole with felodipine. Lovastatin 104-114 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 63-69 8689812-3 1996 Lovastatin is metabolized by CYP3A4. Lovastatin 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 29-35 8689812-13 1996 Inhibition of CYP3A4-mediated metabolism probably explains the increased toxicity of lovastatin caused not only by itraconazole but also by cyclosporine, erythromycin, and other inhibitors of CYP3A4. Lovastatin 85-95 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 14-20 8689812-13 1996 Inhibition of CYP3A4-mediated metabolism probably explains the increased toxicity of lovastatin caused not only by itraconazole but also by cyclosporine, erythromycin, and other inhibitors of CYP3A4. Lovastatin 85-95 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 192-198 33459228-7 2021 The statins like Simvastatin, Lovastatin, and Atorvastatin are substrates of CYP3A4 enzyme and P-glycoprotein and their concomitant use with the drugs inhibiting or inducing them would result in changes in plasma concentrations and toxicity/efficacy. Lovastatin 30-40 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 77-83 33237691-13 2000 One needs to be aware that certain drugs that are used to treat COVID-19 infections may interact with lipid lowering drugs. Remdesivir is metabolized by the Cyp3A4 pathway and statins that are also metabolized by this pathway should be avoided (atorvastatin, simvastatin, and lovastatin). Lovastatin 275-285 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 156-162 31628882-6 2020 The 16 cases of statin-clarithromycin adverse drug reactions (rhabdomyolysis (n = 14) or less severe clinical myopathy) involved a CYP3A4-metabolized statin (simvastatin, lovastatin or atorvastatin). Lovastatin 171-181 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 131-137 27605198-5 2016 Three commonly used statins-simvastatin, atorvastatin and lovastatin-are metabolised by the liver enzyme CYP3A4. Lovastatin 58-68 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 105-111 30808332-6 2019 CONCLUSION: Simvastatin, as well as lovastatin, because of their CYP3A4 metabolism, and to a lesser extent atorvastatin, which is only partially metabolized by CYP3A4, are the HMG-CoA reductase inhibitors with the greatest risk of drug interactions and should not be used in patients under HIV-therapy. Lovastatin 36-46 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 65-71 27967318-0 2017 Effect of polymorphisms in CYP3A4, PPARA, NR1I2, NFKB1, ABCG2 and SLCO1B1 on the pharmacokinetics of lovastatin in healthy Chinese volunteers. Lovastatin 101-111 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 27-33 27967318-1 2017 AIM: This study examined whether gene polymorphisms (CYP3A4, ABCG2, SLCO1B1, NR1I2, PPARA and NFKB1) influenced the pharmacokinetics of lovastatin in Chinese healthy subjects. Lovastatin 136-146 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 53-59 26765458-1 2016 Some statins (simvastatin, lovastatin, and atorvastatin) are metabolized by cytochrome P450s 3A4 (CYP3A4). Lovastatin 27-37 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 76-96 26765458-1 2016 Some statins (simvastatin, lovastatin, and atorvastatin) are metabolized by cytochrome P450s 3A4 (CYP3A4). Lovastatin 27-37 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 98-104